FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to the use of therapeutically effective amount of a compound selected from N-[(1-acryloylpiperidine-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine, its pharmaceutically suitable salts and tautomers, including tautomer mixtures in all ratios, and 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidine-4-yl)amino)methyl)-4-fluoropiperidine-1-yl)prop-2-en-1-one, its pharmaceutically suitable salts and tautomers, including tautomer mixtures in all ratios, for the treatment or prevention of multiple sclerosis.
EFFECT: treatment or prevention of multiple sclerosis (hereinafter – MS), including relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive-relapsing MS (PRMS), using compounds according to the invention.
4 cl, 21 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF MALIGNANT TUMOR USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | 2016 |
|
RU2765154C2 |
| PYRIDINES, PYRIMIDINES AND PYRAZINES AS BRUTON'S TYROSINE KINASE INHIBITORS AND USE THEREOF | 2014 |
|
RU2712220C2 |
| PURINONE COMPOUNDS AS KINASE INHIBITORS | 2013 |
|
RU2655388C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
| AMINOPIRIDAZINOVE COMPOUNDS AS PROTEINKINASE INHIBITORS | 2014 |
|
RU2674701C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| HETEROYRYL PYRIDONES AND AZAPIRIDONS WITH ELECTROPHILIC FUNCTIONALITY | 2014 |
|
RU2646758C2 |
| PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2721774C1 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
